Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 6,006

Document Document Title
WO/2006/084934A1
The invention relates to the use of heterocyclic compounds in the preparation of a medicament for regenerating damaged neuronal tissue. In a preferred embodiment of the invention, compounds having formula I are used to produce a medicame...  
WO/2006/084854A2
The present invention relates to 5-imino-5H-[1,2,4]-dithiazol-3-yl-amine and [1,2,4]- dithiazolidine-3,5-diylidene-diamine derivatives as inducers of glutha-thione-S- transferase (GST) and NADPH quinone oxidoreductase (NQO), to methods f...  
WO/2006/085108A1
Therapeutically active anthranilic acid derivatives of Formula (I) wherein R1, R2, W, Y and Z are as defined in the specification, processes for the preparation of said derivatives, pharmaceutical formulations containing the active compo...  
WO2005107762A3
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2006/083271A2
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...  
WO2006064375A9
The present invention relates to novel compounds selected from aminoaryl five-membered ring heterocycles that selectively modulate, regulate and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases imp...  
WO2006034315A3
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R...  
WO2006002088A3
Antitumor compounds based on the a1-adrenoceptor antagonist, doxazosin, as well as compositions and methods of use. The disclosed compounds induce apoptosis in cancer cells.  
WO/2006/072436A1
The present invention relates to compounds of the general formula (I) wherein R1 is-OR1’,-SR1’ or is a heterocycloalkyl group; R1’ is lower alkyl, lower alkyl substituted by halogen or is -(CH2)n-cycloalkyl; R2 is-S(O)2-lower alkyl...  
WO/2006/069685A1
The invention relates to compounds of formula (I), where A1, A2, R1, R2, R3, R4, R5 and Y have the meanings given in the description, methods and intermediates for production thereof and use thereof for the prevention of pests.  
WO/2006/068821A2
The present invention relates to intermediate compounds useful for the preparation of 1,2,5-thiadiazole compounds, including unsymmetrically substituted compounds such as 4-(3-secondary amino-2-hydroxy-propoxy)-1,2,5-thiadiazole compound...  
WO/2006/064375A1
The present invention relates to novel compounds selected from aminoaryl five-membered ring heterocycles that selectively modulate, regulate and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases imp...  
WO2006064375A2
The present invention relates to novel compounds selected from aminoaryl five-membered ring heterocycles that selectively modulate, regulate and/or inhibit signal transduction mediated by certain native and/or mutant tyrosine kinases imp...  
WO2005085188A3
The present invention provides novel compounds and pharmaceutical compositions thereof, as well as methods for using the compounds and pharmaceutical compositions for treating tumors.  
WO/2006/062224A1
An SGLT inhibitor comprising a compound of the formula: (&Verbar ) wherein the ring A is an optionally substituted ring; R1 is an optionally substituted hydrocarbon group, etc.; each of R2 and R3 independently is a hydrogen atom, an opti...  
WO/2006/062093A1
An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substi...  
WO2006047772A3
A compound for spacing nonlinear optical chromophores of the Formula I and the commercially acceptable salts, solvates and hydrates thereof, wherein R1,R2,R3, R4, W, X, Y, Z, Q1,Q2,Q4 and L have the definitions provided herein.  
WO2006030211A3
Compounds of formula: (I) are found to antagonise N-type calcium channels wherein: - A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C3-C6 carbocycl...  
WO/2006/054652A1
An FAAH inhibitor; and a preventive/therapeutic agent for cerebrovascular disorders and a preventive/therapeutic agent for sleep disorders which each contains the inhibitor. The FAAH inhibitor is a compound represented by the formula (I0...  
WO/2006/050830A1
The invention relates to substituted benzoylguanidines of formula (I), where R1 to R8, X and Y have the meanings given in the claims and the pharmaceutically-acceptable salts thereof which are substituted acylguanidines and inhibit cellu...  
WO/2006/051704A1
An imine compound represented by the formula (X) (wherein A represents a heterocyclic group; R1, R2, and R3 each represents hydrogen, halogeno, C1-10 alkyl optionally substituted by haloaryl, C3-10 cycloalkyl, C1-6 haloalkyl, C1-10 alkox...  
WO2005012275A3
Certain amidophenyl-sulfanylamino-benzo[1,2,5]thiadiazole compounds are CCK2 modulators useful in the treatment of CCK2 mediated diseases.  
WO2005097817A3
The present invention relates to processes and reagents for oligonucleotide synthesis and purification. One aspect of the present invention relates to compounds useful for activating phosphoramidites in oligonucleotide synthesis. Another...  
WO/2006/044456A1
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particu...  
WO2005087752A3
The invention relates to novel aminoalkanol derivatives and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a collection of diseases, disord...  
WO2006016724A3
A liquid-crystalline compound of the following formula:wherein Y11, Y12 and Y13 are methine or N; L1, L2 and L3 are single bond or divalent group; H1, H2 and H3 are formula (DI-A) or (DI-B); YA1, YA2, YB1 and YB2 are methine or N; XA and...  
WO/2006/034315A2
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R...  
WO/2006/030211A2
Compounds of formula: (I) are found to antagonise N-type calcium channels wherein: - A is a 5- to 10-membered heteroaryl or heterocyclyl moiety, said moiety being optionally fused to a phenyl, 5- to 6-membered heteroaryl, C3-C6 carbocycl...  
WO2005092873A3
The invention discloses a new compounds as per general formula (I): where -R stands for: alkyl, alkenyl, aryl, substituted aryl (with chlorine, alkyl, alkoxyl, -CF3, CN, -NO2), phenoxyphenyl, or morpholinoalkyl. The new compounds are app...  
WO/2006/028970A1
Provided herein are compounds and compositions for modulation of tyrosine phosphatase activity. In one embodiment, compounds and compositions for inhibiting protein tyrosine phosphatase activity are provided. In another embodiment, provi...  
WO2006015004A3
A white light-emitting electroluminescent device having an emissive layer that includes a green light-emitting compound and a red light-emitting compound dispersed in a blue light-emitting host.  
WO/2006/019020A1
Urea derivatives having excellent DGAT inhibiting activity or pharmacologically acceptable salts thereof, namely, urea derivatives represented by the general formula (I) or pharmacologically acceptable salts thereof: (I) wherein R1 is C6...  
WO/2006/014413A1
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheros...  
WO/2006/014134A1
Compounds of formula: (chemical formula to be inserted here - please see paper copy) wherein Ar1 is as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepar...  
WO/2006/015004A2
A white light-emitting electroluminescent device having an emissive layer that includes a green light-emitting compound and a red light-emitting compound dispersed in a blue light-emitting host.  
WO/2006/014357A1
Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atheros...  
WO/2006/010751A1
The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof, in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative ...  
WO/2006/008196A1
The present invention relates to a process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates of compounds having at least a hydroxyl or thiol functional group, according to the following ...  
WO2005092304A3
Compounds of formula (I), and pharmaceutically acceptable salts thereof, may be used in therapy, for example as antifungal agents, wherein: R1, R2 and R3 are as defined herein. Certain compounds of formula (I) are also provided. Compound...  
WO/2006/009134A1
A novel fungicide that exhibits a wide disease control spectrum against pathogenic fungi acting on various crops and helps resolve worsening resistant strain problems. There are provided diamine derivatives of the formula (1), a process ...  
WO/2006/010082A1
In general, the present invention relates to compounds capable of inhibiting P38, methods for inhibiting P38 in vivo or in vitro, diagnostics for determining activity in the treatment of P38 and/or cytokine-associated conditions and meth...  
WO/2006/002284A1
This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of...  
WO/2005/121110A1
Compounds of Formula (I) wherein: R1 is hydroxymethyl; R2 is selected from -C(O)NR4R5, SO2NR4R5, S(O)pR4 and HET-2; HET-1 is a 5- or 6-membered, optionally substituted C-linked heteroaryl ring; HET-2 is a 4-, 5- or 6-membered, C- or N-li...  
WO/2005/118575A1
The invention relates to compounds of formula (I) wherein Ar, X, R1, R2, R3 and R4 are as defined herein and pharmaceutical compositions thereof useful, either alone or in combination with other therapeutic agents as reverse transcriptas...  
WO2005058298B1
The present invention provides FK228 analogs and methods of making and using the same. Such analogs are potent inhibitors of histone deacetylase and, in certain embodiments, are capable of specifically targeting cancerous cells and tissu...  
WO2004058911A3
The invention relates to the improvement of organic electroluminescent devices. Said devices are characterised in that the emitting layer (EML) consists of a mixture of two substances, one having hole-conductive characteristics and the o...  
WO/2005/115995A1
An amine compound having a specific structure; and an organic electroluminescent element which comprises an anode and a cathode and, sandwiched therebetween, an organic thin film layer consisting of one or more layers comprising at least...  
WO/2005/113527A1
The present invention relates to novel tetrahydronaphthylpiperazines derivatives, that are compounds of the formula (I) wherein R1, R2 and R6 are as defined herein, X is CH2 or O, A is a group of the formula (G1, G2, G2a, G3, G4, G5 or G...  
WO/2005/107762A2
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO2005058298A3
The present invention provides FK228 analogs and methods of making and using the same. Such analogs are potent inhibitors of histone deacetylase and, in certain embodiments, are capable of specifically targeting cancerous cells and tissu...  

Matches 601 - 650 out of 6,006